ECMO Types: Complete Guide to Extracorporeal Membrane Oxygenation Configurations

Extracorporeal membrane oxygenation in neonates represents one of the most critical and technically demanding applications of life-support medicine. ECMO — short for extracorporeal membrane oxygenation — is a form of prolonged cardiopulmonary bypass used when the heart, lungs, or both have failed to such a degree that conventional therapies are insufficient. Understanding the different ecmo types is essential for clinicians, perfusionists, nurses, and respiratory therapists who manage these complex circuits at the bedside.

At its core, every ECMO configuration removes blood from the patient's venous system, passes it through an artificial membrane lung where carbon dioxide is removed and oxygen is added, and then returns oxygenated blood to the circulation. The key distinction among ECMO types lies in where that blood is returned: back into the venous system (veno-venous, or VV ECMO) or directly into the arterial system (veno-arterial, or VA ECMO). Each configuration carries distinct indications, cannulation strategies, hemodynamic consequences, and complication profiles that clinicians must fully understand before initiating support.

The extracorporeal membrane oxygenation procedure has evolved dramatically since its first successful neonatal application in the 1970s. Modern centrifugal pumps, polymethylpentene hollow-fiber oxygenators, and heparin-coated circuits have made ECMO safer, more durable, and accessible to a broader range of patients — from premature neonates weighing under two kilograms to adults with refractory cardiac arrest. Knowing which configuration to deploy, when to deploy it, and how to troubleshoot the extracorporeal membrane oxygenation circuit are skills that define expert ECMO practice.

Neonatal ECMO remains the historical backbone of the field. Conditions such as meconium aspiration syndrome, congenital diaphragmatic hernia, persistent pulmonary hypertension of the newborn, and sepsis-induced respiratory failure have all been successfully treated with ECMO when maximal conventional therapy has failed. Survival rates for neonatal respiratory ECMO hover around 75 percent according to Extracorporeal Life Support Organization (ELSO) registry data — a remarkable outcome given the severity of illness in this population.

Beyond neonates, extracorporeal membrane oxygenation for adults has expanded substantially over the past two decades. The H1N1 influenza pandemic in 2009 and the COVID-19 pandemic beginning in 2020 both drove surges in adult VV ECMO utilization for severe acute respiratory distress syndrome. Simultaneously, the use of VA ECMO for cardiogenic shock, refractory cardiac arrest, and as a bridge to ventricular assist devices or heart transplantation has grown in cardiac surgery and interventional cardiology centers worldwide.

This article provides a comprehensive overview of every major ECMO type — VV, VA, and hybrid configurations — along with their indications, circuit components, cannulation strategies, and clinical management considerations. Whether you are preparing for the ELSO certification examination, studying for a respiratory care board examination, or simply expanding your clinical knowledge of extracorporeal support, this guide will give you a structured, evidence-based framework for understanding how ECMO configurations differ and why those differences matter at the bedside.

By the end of this guide, you will understand the physiological rationale behind each ECMO type, be able to identify the appropriate configuration for common clinical scenarios, and have a clear picture of the key safety checks and troubleshooting steps that keep patients safe on extracorporeal support. Real-world data, circuit diagrams in prose, and step-by-step clinical reasoning are woven throughout to ensure that this knowledge translates directly into practice.

Venovenous extracorporeal membrane oxygenation and veno-arterial ECMO are the two foundational configurations, and the clinical decision between them hinges primarily on whether the patient has cardiac dysfunction in addition to respiratory failure. In VV ECMO, a large drainage cannula typically placed in the right femoral vein or right internal jugular vein removes desaturated blood from the venous circulation.

After passing through the oxygenator, fully oxygenated blood is returned to the right atrium, where it mixes with native venous return before being pumped forward by the patient's own right ventricle. This means VV ECMO provides no direct hemodynamic support — the heart must still be capable of maintaining adequate cardiac output on its own.

VA ECMO, by contrast, drains blood from the venous side and returns it to the arterial circulation — classically the femoral artery in adults or the carotid artery in neonates — bypassing the heart entirely and providing direct mechanical circulatory support. This makes VA ECMO the preferred configuration for refractory cardiogenic shock, cardiac arrest with return of spontaneous circulation but persistent hemodynamic instability, acute myocarditis, massive pulmonary embolism, and post-cardiotomy cardiac failure.

The trade-off is significant: VA ECMO imposes retrograde aortic flow in femoral configurations, which increases left ventricular afterload and can cause left heart distension if the native left ventricle is severely dysfunctional. Managing this requires strategies such as intra-aortic balloon pump placement or percutaneous left ventricular venting.

The extracorporeal membrane oxygenation circuit itself consists of several key components regardless of configuration: the drainage cannula, the tubing circuit, the pump (centrifugal or roller), the membrane oxygenator, a heat exchanger to maintain patient normothermia, and the return cannula. Modern circuits also incorporate inline flow probes, pressure monitors, and continuous oximetry sensors to allow real-time circuit surveillance. Understanding how each component contributes to overall circuit function — and how each can fail — is a foundational competency for anyone managing ECMO at the bedside.

One nuance that separates VV and VA ECMO management is the interpretation of oxygen saturation data. On VV ECMO, the pre-oxygenator (drainage) saturation reflects the mixture of native venous blood and recirculated oxygenated blood from the return cannula. High pre-oxygenator saturations suggest significant recirculation — a state where oxygenated blood is being immediately re-suctioned into the drainage cannula before reaching the systemic circulation.

Recirculation is a common challenge in VV ECMO and can be minimized by optimizing cannula positioning, increasing the distance between drainage and return cannula tips, or switching to a bicaval dual-lumen cannula design that physically separates drainage and return orifices.

In VA ECMO, pulse oximetry becomes unreliable as a sole monitor of circuit adequacy because retrograde arterial flow from the ECMO circuit and antegrade cardiac output from the native heart create competing bloodstreams with potentially different oxygen contents. This phenomenon — sometimes called the Harlequin syndrome or North-South syndrome — occurs when the upper body is perfused by poorly oxygenated native cardiac output while the lower body receives well-oxygenated ECMO flow. Clinicians must monitor right radial arterial blood gases and cerebral oximetry to ensure adequate upper-body oxygenation on peripheral VA ECMO.

Anticoagulation management represents a critical and nuanced aspect of ECMO care that spans all configuration types. The standard anticoagulant used in most ECMO programs is unfractionated heparin, titrated to maintain an activated clotting time between 180 and 220 seconds, or an anti-Xa level of 0.3 to 0.7 units per milliliter, depending on institutional protocol. The balance between preventing circuit thrombosis and avoiding life-threatening bleeding complications — particularly intracranial hemorrhage in neonates — is the central management challenge in ECMO anticoagulation. Bivalirudin is increasingly used as an alternative, particularly in patients with heparin-induced thrombocytopenia.

The extracorporeal membrane oxygenation circuit diagram — whether physical or conceptual — always illustrates this fundamental loop: venous drainage from the patient, mechanical pump driving flow, membrane oxygenator for gas exchange, heat exchanger for temperature control, and arterial or venous return to the patient. Mastering this mental model allows clinicians to rapidly localize problems when circuit pressures change, flows drop, or oxygenation deteriorates unexpectedly.

Extracorporeal membrane oxygenation in neonates carries unique physiological, technical, and ethical dimensions that set it apart from adult ECMO practice. Neonatal patients have immature coagulation systems, fragile cerebrovascular anatomy with a high risk of intraventricular hemorrhage, and rapidly changing hemodynamics that demand continuous vigilance and experienced nursing care.

The most common neonatal indications for ECMO include meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, congenital diaphragmatic hernia, neonatal sepsis, and respiratory distress syndrome unresponsive to surfactant and high-frequency oscillatory ventilation. Neonatal ECMO programs typically use VA configurations via right common carotid artery and right internal jugular vein cannulation — an approach that sacrifices the right common carotid artery permanently, a trade-off that remains a subject of ongoing follow-up study.

The oxygenation index is the primary trigger criterion for neonatal ECMO initiation. An oxygenation index greater than 40 on two consecutive arterial blood gas measurements within a one-hour period, or persistent OI above 25 despite maximal conventional therapy, typically indicates that ECMO should be considered. The oxygenation index is calculated as: (Mean Airway Pressure × FiO2 × 100) divided by PaO2. Centers using this threshold report that delaying ECMO beyond an OI of 40 is associated with worsening outcomes, suggesting a narrow therapeutic window in critically ill neonates.

Congenital diaphragmatic hernia (CDH) represents one of the most complex neonatal ECMO indications because pulmonary hypoplasia — not just reversible pulmonary hypertension — is often the primary pathophysiology. Unlike meconium aspiration syndrome, where full lung recovery is expected, CDH patients may have anatomically reduced lung mass that limits pulmonary function regardless of ECMO support duration.

ECMO in CDH is therefore most appropriately viewed as a bridge to surgical repair of the diaphragmatic defect and subsequent lung growth, rather than as a bridge to pulmonary recovery. ELSO registry data suggest CDH survival on ECMO is approximately 50 to 55 percent — lower than other neonatal indications, reflecting this underlying anatomic limitation.

Pediatric ECMO extends these principles to older infants and children, where cardiac indications become proportionally more common. Children with myocarditis, post-operative congenital heart disease repair failure, and refractory arrhythmias are frequent VA ECMO candidates in pediatric cardiac centers. The transition from neonatal to pediatric ECMO practice involves larger cannulas, higher flow targets, and different anticoagulation management. Pediatric patients can also tolerate VV ECMO more robustly than neonates once they have grown sufficiently for bicaval dual-lumen cannula placement, typically around 10 to 15 kilograms body weight.

Neurological complications remain the most feared adverse outcome in neonatal ECMO. Intracranial hemorrhage, ischemic stroke, periventricular leukomalacia, and seizures occur in a significant minority of neonatal ECMO patients and are associated with long-term neurodevelopmental impairment. Head ultrasound is typically performed daily during the first several days of neonatal ECMO to detect intracranial hemorrhage early. A Grade III or IV intraventricular hemorrhage discovered during ECMO is generally considered a contraindication to continuation, as ongoing anticoagulation will dramatically worsen hemorrhage expansion and subsequent neurological injury.

Weaning from neonatal ECMO is a structured process guided by assessment of native lung recovery. As pulmonary compliance improves and FiO2 requirements decrease, the sweep gas fraction of inspired oxygen on the ECMO circuit is reduced while ventilator support is incrementally increased.

A trial off ECMO — during which the circuit is clamped while the patient breathes on the ventilator alone — is performed when the team believes the patient has adequate native lung function. If the patient maintains acceptable gas exchange for a period of two to four hours during the clamp trial, decannulation proceeds. If not, ECMO flows are restored and the recovery assessment continues.

Long-term follow-up data from neonatal ECMO survivors reveal that while many children develop normally, a subset experiences neurodevelopmental delays, hearing loss, and behavioral difficulties. The ECMO survivor community has driven advocacy for comprehensive developmental follow-up clinics that assess children at regular intervals through school age. For families, this means that the end of ECMO is not the end of medical engagement — but the beginning of a long-term developmental surveillance relationship between families, neonatologists, and pediatric developmental specialists.

Extracorporeal membrane oxygenation for adults has undergone a dramatic transformation since the early 2000s, propelled by improvements in circuit technology, growing operator experience, and a series of high-profile clinical trials and registry studies that clarified both the benefits and limitations of adult ECMO. The CESAR trial in 2009 demonstrated improved survival without severe disability when patients with severe ARDS were transferred to an ECMO-capable center, though methodological limitations prevented definitive conclusions about ECMO versus optimized conventional management alone.

The subsequent EOLIA trial in 2018 showed a non-significant 11 percent absolute reduction in 60-day mortality with early VV ECMO for severe ARDS compared to conventional management, with significant crossover from control to ECMO in deteriorating patients. Together, these trials have established VV ECMO as a reasonable rescue therapy for severe ARDS in centers with adequate expertise.

The role of extracorporeal membrane oxygenation and COVID-19 intersected dramatically during the SARS-CoV-2 pandemic. COVID-19-related ARDS drove unprecedented surges in VV ECMO utilization at specialized centers worldwide. Early reports from institutions with significant ECMO experience showed survival rates of 60 to 70 percent for carefully selected COVID-19 patients placed on VV ECMO — figures comparable to pre-pandemic ARDS survival on ECMO. However, concerns about resource allocation, circuit supply shortages, and the extremely prolonged ECMO runs required in some COVID-19 patients (sometimes exceeding 30 to 60 days) raised important questions about system capacity and patient selection criteria during pandemic surge conditions.

VA ECMO for cardiogenic shock and cardiac arrest has grown into a major subspecialty within interventional cardiology and cardiac surgery. ECMO-facilitated resuscitation, or ECPR — the practice of initiating VA ECMO during ongoing cardiopulmonary resuscitation in patients with refractory cardiac arrest — has been adopted at a growing number of cardiac arrest centers.

Observational data from high-volume ECPR programs suggest meaningful survival rates in highly selected patients with witnessed arrest, cardiac etiology, and rapid ECMO cannulation times. Randomized controlled trials, including the ARREST trial, have provided early evidence supporting ECPR over standard ACLS in certain settings, though patient selection and rapid execution are critical determinants of outcome.

The extracorporeal membrane oxygenation machine price remains a significant barrier to ECMO adoption in lower-resource settings globally. A complete ECMO system — including the console, pump, oxygenator, heater-cooler, and monitoring equipment — can cost between $30,000 and $100,000 or more depending on manufacturer and configuration. Disposable circuit components add thousands of dollars per run. Training programs, dedicated nursing staff, perfusionist coverage, and institutional credentialing requirements further increase the true cost of maintaining an ECMO program. These economic realities mean that high-quality ECMO care remains concentrated at academic medical centers and high-volume regional referral hospitals in the United States.

Mobile ECMO — the practice of initiating ECMO at a referring hospital and transporting the patient on circuit to a higher-level center — has expanded access to extracorporeal support for patients in geographic regions without a local ECMO program.

Specialized mobile ECMO teams carry compact, battery-powered centrifugal pump consoles along with full circuit supplies and trained personnel to retrieve patients who cannot safely be transported on conventional life support. The risks of transport on ECMO are significant but manageable with experienced teams, and outcomes for transported ECMO patients are comparable to those cannulated at the receiving center when patient selection is appropriate.

Looking at the future of ECMO types, miniaturized extracorporeal support devices and wearable ECMO concepts are in active development and clinical investigation. These systems aim to provide partial respiratory or circulatory support at lower flow rates, reduced anticoagulation intensity, and with smaller cannulas — enabling earlier initiation in less critically ill patients or prolonged support as a bridge to lung transplantation in ambulatory patients. The Novalung and related devices already occupy this space in some centers, and ongoing research is pushing toward fully implantable artificial lung devices that could replace or substantially extend conventional ECMO capabilities within the next decade.

For clinicians and candidates preparing for ECMO certification examinations, mastering the distinctions between adult and neonatal ECMO types — including their unique physiological rationales, cannulation strategies, monitoring requirements, and weaning approaches — is essential. The ELSO certification examination tests candidates across all patient populations and circuit types, and a strong conceptual framework built around the physiology of VV versus VA support will provide the scaffolding needed to answer both straightforward knowledge questions and complex clinical-reasoning scenarios with confidence.

Preparing to work with ECMO — whether as a new perfusionist, a critical care nurse stepping into an ECMO center, or a physician completing fellowship training — requires a structured approach that goes beyond reading about circuit types. The most effective ECMO clinicians develop competence through a combination of formal didactic education, simulation-based training, preceptored bedside experiences, and ongoing quality review of ECMO cases at their center. Understanding the conceptual framework of ECMO types is the necessary first step, but translating that knowledge into safe, confident bedside management requires deliberate, supervised practice.

When studying ECMO types for an exam or clinical orientation, start with the physiological underpinnings of each configuration before memorizing specific protocols. Ask yourself: Why does VV ECMO fail to help a patient in cardiogenic shock? Why does VA ECMO increase LV afterload? What would happen to systemic oxygen delivery if the ECMO pump flow suddenly dropped by half? This kind of mechanistic reasoning will serve you far better than rote memorization and will prepare you to manage the unexpected scenarios that ECMO inevitably presents at the bedside.

Simulation is increasingly available for ECMO training through high-fidelity mannequin-based platforms and circuit simulation models that allow teams to practice emergencies — including air embolism, oxygenator failure, pump malfunction, and sudden circuit disconnection — without risk to a patient. ELSO has published ECMO specialist training curricula that incorporate simulation milestones, and many ECMO centers require simulation completion before new team members are credentialed for unsupervised ECMO management. Seek out these opportunities early and treat each simulation scenario as a high-stakes real event to build genuine procedural confidence.

Documentation and communication are among the most underemphasized skills in ECMO practice. Every circuit assessment, troubleshooting event, anticoagulation adjustment, and clinical change must be clearly documented in the medical record. Bedside handoffs between ECMO specialists — which typically occur every 8 to 12 hours — must include a structured review of circuit parameters, recent events, outstanding concerns, and planned interventions. Poorly communicated handoffs are a leading contributing factor in ECMO adverse events, and developing a standardized handoff checklist is a quality initiative that every ECMO program should prioritize.

Understanding pharmacokinetics on ECMO is critical because the extracorporeal circuit significantly alters the volume of distribution and clearance of many drugs. Sedatives, analgesics, antibiotics, and antifungals may be sequestered in the circuit tubing and oxygenator membrane, resulting in sub-therapeutic plasma concentrations despite apparently adequate dosing. Lipophilic drugs like fentanyl, midazolam, and voriconazole are especially prone to circuit sequestration. Clinicians managing ECMO patients must be prepared to use higher-than-standard drug doses and to monitor drug levels more aggressively than in non-ECMO patients to ensure therapeutic efficacy.

For those preparing for formal ECMO certification through ELSO or through a specialty board examination that includes ECMO content, practice questions are one of the highest-yield study tools available. Working through ECMO practice test questions forces active recall of circuit management principles, helps identify knowledge gaps before the examination, and familiarizes candidates with the style and complexity of questions they will encounter. Focus particularly on questions about VV versus VA indication selection, anticoagulation management, troubleshooting low-flow states, and neonatal-specific management — these represent the highest-density content areas on most ECMO-related examinations.

Finally, engage actively with the ELSO community and its published resources. ELSO maintains registry data, publishes supplementary materials, and convenes annual conferences where cutting-edge ECMO research is presented. Following the ELSO red books — specialty-specific ECMO guidelines covering neonatal, pediatric, cardiac, and adult respiratory applications — gives you access to the consensus recommendations of the world's leading ECMO experts. These documents are updated periodically and represent the gold standard for evidence-based ECMO practice. No single article, textbook chapter, or training course should replace direct engagement with these primary resources as you build your ECMO expertise.